Key result
Menopausal hormone therapy in women <60 or within 10 years of menopause requires prior assessment and guideline-directed management of modifiable cardiovascular disease risk factors.
Why the study?
Escalating interest in menopausal hormone therapy coincides with rising cardiovascular disease risks and acute coronary syndrome hospitalizations in premenopausal women, meaning many women reach menopause with more advanced cardiovascular risk than in the past.
Rising cardiovascular risk in younger women necessitates careful assessment and management of modifiable cardiovascular risk factors using validated calculators prior to initiating menopausal hormone therapy.
Answers are grounded in this paper and cite their sources.
Supports pre-therapy cardiovascular risk assessment in eligible women; leaves open whether validated calculators improve net safety in prospective trials.
Menopause management is in the midst of a paradigm shift as enthusiasm, fueled by the lay press and online influencers, increases amongst women, yielding an escalating interest in hormone therapy (HT) that has not been experienced since the turn of the last century. Updates to regulatory labeling of menopausal HT products include the removal of boxed warnings and language that recommended using the lowest dose for the shortest time while focusing on risks and benefits to those seeking menopause symptom relief—women younger than 60 or within 10 years of menopause. This renewed desire for menopausal HT must be tempered with the understanding that risks for cardiovascular disease (CVD) are also rising in premenopausal women as are hospitalizations for acute coronary syndromes. Factors that contribute to long-term cardiovascular risk include adverse pregnancy outcomes, which are occurring with increasing frequency. The metabolic changes that accompany the menopause transition further complicate a woman's cardiovascular risk profile. Many women today will arrive at menopause with more advanced CVD risk than what was encountered in the past. If women are considering HT for menopausal symptom relief or bone preservation, careful consideration is required to identify and treat modifiable CVD risks—dyslipidemia, glucose intolerance, hypertension, and, increasingly, obesity—to targets established by guidelines before initiating HT. Risk assessment with validated risk calculators can help stratify CVD risk, a factor that determines lipid lowering therapy, and the advisability and choice of menopausal HT. The rising tide of cardiovascular risk does not have to make waves at menopause.
No takes yet. Share an insight, caveat, or question.
Cynthia A. Stuenkel (2026) conducted a review in Cardiovascular disease risk in menopausal and premenopausal women. Menopausal hormone therapy (HT) was evaluated. Menopausal hormone therapy in women <60 or within 10 years of menopause requires prior assessment and guideline-directed management of modifiable cardiovascular disease risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: